Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Centessa Pharmaceuticals (CNTA) FCF Margin: 2022-2025

Historic FCF Margin for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Sep 2025 value amounting to 2,025.81%.

  • Centessa Pharmaceuticals' FCF Margin rose 118800.00% to 2,025.81% in Q3 2025 from the same period last year, while for Sep 2025 it was -2,683.33%, marking a year-over-year decrease of 396382.00%. This contributed to the annual value of 1,408.22% for FY2024, which is 375042.00% up from last year.
  • Per Centessa Pharmaceuticals' latest filing, its FCF Margin stood at 2,025.81% for Q3 2025, which was up 160.22% from 778.50% recorded in Q2 2025.
  • Centessa Pharmaceuticals' FCF Margin's 5-year high stood at 3,636.18% during Q2 2022, with a 5-year trough of -381.64% in Q1 2025.
  • Over the past 3 years, Centessa Pharmaceuticals' median FCF Margin value was 1,474.34% (recorded in 2024), while the average stood at 1,326.69%.
  • Data for Centessa Pharmaceuticals' FCF Margin shows a peak YoY increase of 118,800bps (in 2025) and a maximum YoY decrease of 185,598bps (in 2025) over the last 5 years.
  • Centessa Pharmaceuticals' FCF Margin (Quarterly) stood at 2,370.22% in 2022, then crashed by 116,096bps to 1,209.26% in 2023, then soared by 51,724bps to 1,726.50% in 2024, then skyrocketed by 118,800bps to 2,025.81% in 2025.
  • Its FCF Margin was 2,025.81% in Q3 2025, compared to 778.50% in Q2 2025 and -381.64% in Q1 2025.